pamidronate has been researched along with Fibrocartilaginous Dysplasia of Bone in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 9.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| "Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome." | 6.69 | Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000) |
| "Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function." | 5.10 | Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002) |
| "Pamidronate treatment can ameliorate the course of bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome." | 2.69 | Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome. ( Bertelloni, S; Buzi, F; de Sanctis, C; Lala, R; Matarazzo, P; Rigon, F, 2000) |
| "Fibrous dysplasia of bone is a genetic, non-inheritable disease, characterized by bone pain, bone deformities and fracture, involving one or several bones." | 2.44 | Fibrous dysplasia of bone and McCune-Albright syndrome. ( Chapurlat, RD; Orcel, P, 2008) |
| "Fibrous dysplasia of bone is a disease that can involve one or several bones and is characterized by bone deformities, pain and iterative fractures." | 2.41 | Fibrous dysplasia of bone. ( Chapurlat, RD; Meunier, PJ, 2000) |
| "Fibrous dysplasia of bone is characterized by focal replacement of normal bone and marrow with abnormal bone and fibrous tissue." | 1.35 | Nephronophthisis-like nephritis associated with fibrous dysplasia of bone. ( Antignac, C; Bacchetta, J; Bouvier, R; Chapurlat, R; Cochat, P; Delmas, PD; Dubourg, L; Kohler, R, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (23.53) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 2 (11.76) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Chapurlat, R | 3 |
| Legrand, MA | 1 |
| Florez, H | 1 |
| Mandelikova, S | 1 |
| Filella, X | 1 |
| Monegal, A | 1 |
| Guañabens, N | 1 |
| Peris, P | 1 |
| Akasbi, N | 1 |
| Abourazzak, FE | 1 |
| Talbi, S | 1 |
| Tahiri, L | 1 |
| Harzy, T | 1 |
| Bacchetta, J | 1 |
| Bouvier, R | 1 |
| Antignac, C | 1 |
| Dubourg, L | 1 |
| Kohler, R | 1 |
| Delmas, PD | 4 |
| Cochat, P | 1 |
| Matarazzo, P | 2 |
| Lala, R | 2 |
| Masi, G | 1 |
| Andreo, M | 1 |
| Altare, F | 1 |
| de Sanctis, C | 2 |
| Saenger, P | 1 |
| Rincon, M | 1 |
| Parisi, MS | 1 |
| Oliveri, B | 1 |
| Mautalen, CA | 1 |
| Chapurlat, RD | 4 |
| Hugueny, P | 1 |
| Meunier, PJ | 5 |
| Orcel, P | 1 |
| Liens, D | 2 |
| Weinstein, RS | 1 |
| Bertelloni, S | 1 |
| Buzi, F | 1 |
| Rigon, F | 1 |
| Lane, JM | 1 |
| Khan, SN | 1 |
| O'Connor, WJ | 1 |
| Nydick, M | 1 |
| Hommen, JP | 1 |
| Schneider, R | 1 |
| Tomin, E | 1 |
| Brand, J | 1 |
| Curtin, J | 1 |
| Mikosch, P | 1 |
| Pietschmann, P | 1 |
| Kainberger, F | 1 |
| Gallowitsch, HJ | 1 |
| Lind, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome[NCT00001728] | Phase 2 | 40 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pamidronate and Fibrocartilaginous Dysplasia of Bone
| Article | Year |
|---|---|
Fibrous dysplasia of bone and McCune-Albright syndrome.
Topics: Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Fractures, Bone; GTP-Bind | 2008 |
Fibrous dysplasia of bone.
Topics: Adolescent; Anti-Inflammatory Agents; Diphosphonates; Fibrous Dysplasia of Bone; Fibrous Dysplasia, | 2000 |
3 trials available for pamidronate and Fibrocartilaginous Dysplasia of Bone
| Article | Year |
|---|---|
Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
Topics: Adolescent; Adult; Alkaline Phosphatase; Body Height; Bone and Bones; Bone Density; Child; Diphospho | 2002 |
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Topics: Adolescent; Adult; Biomarkers; Biopsy; Bone and Bones; Bone Density; Bone Remodeling; Calcium, Dieta | 1997 |
Pamidronate treatment of bone fibrous dysplasia in nine children with McCune-Albright syndrome.
Topics: Adolescent; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Fibrous Dysplasia of Bone | 2000 |
12 other studies available for pamidronate and Fibrocartilaginous Dysplasia of Bone
| Article | Year |
|---|---|
Bisphosphonates for the treatment of fibrous dysplasia of bone.
Topics: Bone and Bones; Diphosphonates; Fibrous Dysplasia of Bone; Humans; Pamidronate; Quality of Life | 2021 |
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Fa | 2018 |
[Fibrous dysplasia: overview].
Topics: Bone Density Conservation Agents; Chromogranins; Diphosphonates; Fibrous Dysplasia of Bone; GTP-Bind | 2015 |
Nephronophthisis-like nephritis associated with fibrous dysplasia of bone.
Topics: Child; Diphosphonates; Fibrous Dysplasia of Bone; Humans; Kidney; Male; Nephritis; Pamidronate | 2008 |
Precocious puberty: McCune-Albright syndrome and beyond.
Topics: Anti-Inflammatory Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Diphosphonates; | 2003 |
Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia.
Topics: Adolescent; Adult; Alkaline Phosphatase; Bone Density; Case-Control Studies; Collagen; Collagen Type | 2003 |
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
Topics: Administration, Oral; Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; | 2004 |
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
Topics: Adolescent; Adult; Alkaline Phosphatase; Diphosphonates; Female; Fibrous Dysplasia of Bone; Follow-U | 1994 |
Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density.
Topics: Adult; Bone Density; Calcium, Dietary; Collagen; Collagen Type I; Diphosphonates; Female; Fibrous Dy | 1997 |
The nonsurgical treatment of fibrous dysplasia.
Topics: Adolescent; Bone Density; Calcium; Diphosphonates; Ergocalciferols; Female; Fibrous Dysplasia of Bon | 1999 |
Bisphosphonate therapy in fibrous dysplasia.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type | 2001 |
[Paget disease or fibrous dysplasia of the radius?--A case report].
Topics: Diagnosis, Differential; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Sched | 2001 |